GlassScriptPhysician profile
Christopher P Irwin
NPI 1427613736
$1,005.91
in general payments reported to CMS, 2019-2025
19 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $405 · 2023: $217 · 2024: $166 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $166.57 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $128.14 | 2023-2025 | |
| Pfizer INC. | $85.23 | 2023-2025 | |
| Amgen INC. | $72.49 | 2022-2025 | Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $71.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.50 | 2022-2023 | |
| Exact Sciences Corporation | $53.96 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.96 | 2022 | |
| Daiichi Sankyo INC. | $49.05 | 2022 | |
| Lilly USA, LLC | $46.31 | 2022-2023 | Trulicity, Mounjaro |
| Janssen Pharmaceuticals, INC | $41.65 | 2022-2023 | Spravato |
| Inspire Medical Systems, INC. | $39.08 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $37.62 | 2022-2023 | Rexulti |
| Dexcom, INC. | $32.10 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $19.78 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $17.64 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.73 | 2022 | |
| Mylan Specialty L.P. | $12.71 | 2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Irwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.